ESC 365 - Risk of thromboembolic and haemorrhagic events associated with anticoagulation among 11,355 patients with non-valvular atrial fibrillation and thrombocytopenia

ESC Professional Premium Access

Risk of thromboembolic and haemorrhagic events associated with anticoagulation among 11,355 patients with non-valvular atrial fibrillation and thrombocytopenia

Session: Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations

Topic: Oral Anticoagulation

Speaker: Doctor M. Tam (Shatin, HK)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Mark Tam

The Chinese University of Hong Kong, Shatin (Hong Kong)

0 follower

4 more presentations in this session

Predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF

Speaker: Doctor M. Tannu (Durham, US)

Anticoagulation and stroke in hospitalized patients newly diagnosed with secondary atrial fibrillation: a population-based cohort study

Speaker: Doctor H. Abdel-Qadir (Toronto, CA)

Post-operative atrial fibrillation during cardiac rehabilitation: incidence and long-term prognostic value.

Speaker: Doctor S. Rastelli (IT)

Use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation across five stages of chronic kidney diseases

Speaker: Doctor T. Chao (Taipei, TW)

Access the full session

Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations

Speakers: Doctor M. Tam, Doctor M. Tannu, Doctor H. Abdel-Qadir, Doctor S. Rastelli, Doctor T. Chao

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources